Clinical Trial

The Glaucoma Nicotinamide Trial

Study acronym: TGNT
Recruiting
View on ClinicalTrials.gov →
Summary
The Glaucoma Nicotinamide Trial (TGNT) is a prospective, randomized, placebo-controlled double-masked clinical trial composed of two cohorts; The Swedish Glaucoma Nicotinamide Trial (SGNT) and the Vitamin B3 In Glaucoma Study (VBIGS). Patients with open-angle glaucoma (OAG) will be randomized to receive either Nicotinamide or placebo through block randomization stratified by glaucoma subtype with a 1:1 allocation.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-03-02; most recent amendment 2023-07-25.
Status change: Not Yet Recruiting → Recruiting 2022-05-25
Trial Details
NCT Number NCT05275738
Lead Sponsor Umeå University
Collaborators: Center for Eye Research Australia, Karolinska Institutet, Singapore National Eye Centre, Duke-NUS Graduate Medical School, University of Melbourne, University of Adelaide, Lund University, Linkoeping University, Göteborg University
Conditions Glaucoma
Enrollment 660 participants
Start Date 2022-05-18
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-07-27